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OBJECTIVES: Pharmacotherapy costs represents huge burden
for health institutions. The aim of the study is to compare pre-
scribing practice and cost of outpatient hypertension pharmaco-
therapy between Bulgaria and Serbia. METHODS: A one year
retrospective study from the point of view of the health system
was performed, based on the collected reimbursed prescriptions
with diagnosis AH (I10–I11) and for its complications—heart
failure (I.50); sequelae of cerebrovascular disease (I.69); angina
pectoris (I.20). Therapy was analysed according to the complex-
ity (mono-, di-, etc.), frequency of prescribed medicines, reim-
bursed drug prices, and patient co-payment. To calculate the cost
of the outpatient therapy was build a decision tree model match-
ing the frequency of particular brand name prescribing, their
prices, and complexity of therapy. RESULTS: The relative share
of uncomplicated hypertension is comparable (67% in Serbia
and 65% in Bulgaria). The ACE inhibitors are the ﬁrst choice for
hypertension treatment in both countries. Hypertension mono-
therapy differs signiﬁcantly (47% in Bulgaria and 6% in Serbia),
while di-therapy is comparable (35% and 30%). Among the
complications prevails prescriptions for angine pectoris (70% in
Serbia and 42% in Bulgaria) and heart failure (7% and 26%).
The complications are usually treated with more than one medi-
cine in Serbia while the monotherapy in Bulgaria is 66%. By
including the cost and prevalence of mono-, di- etc therapy in the
“decision tree” model we receive that the waged monthly cost of
outpatient pharmacotherapy per patient with uncomplicated
hypertension account for €12.56 in Serbia and €6.90 in Bulgaria.
The total monthly cost of hypertension considering the chance of
having complications is €13.39 in Serbia and €8.23 in Bulgaria.
Patient co-payment in Bulgaria is higher. CONCLUSIONS: Inter-
national cost comparisons are possible but depend on many
external factors as regulatory and price control measures, pre-
scribing habits, reimbursement policy.
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COST-EFFECTIVENESS OF GADOFOSVESET-ENHANCED
MAGNETIC RESONANCE (MR) ANGIOGRAPHY FORTHE
PATIENTS WITH CHRONIC PERIPHERAL ARTERIAL
OBSTRUCTIVE DISEASE (PAOD) IN KOREA
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Seoul National University, Seoul, South Korea
OBJECTIVES: To assess the cost-effectiveness of gadofosveset-
enhanced MR Angiography (VV-MRA) compared with conven-
tional extracellular contrast agents enhanced MRA (EC-MRA),
and computed-tomography angiography (CTA) for the diagnosis
and treatment of chronic PAOD patients in Korea. METHODS:
It is assumed that diagnostic test affects the treatment decision
and the patient’s health outcome consequently. Decision analytic
model based on the published clinical guidelines for the PAOD
diagnosis and treatment was constructed. We adopted societal
perspective and 1 year time horizon. The sensitivity and speci-
ﬁcity of imaging diagnostic tests were extracted from published
studies to estimate probabilities of diagnostic positive and posi-
tive predictability. The studies that used the conventional angiog-
raphy or digital subtraction angiography as a gold standard were
included. Costs broke down into imaging costs and treatment
costs. They were collected from experts’ panel survey and
National Health Insurance Claims database. All costs were
expressed in 2007. Quality weights for health outcomes were
extracted from published studies. Incremental cost-effectiveness
ratio was calculated and sensitivity analysis for various uncertain
parameters was conducted. RESULTS: For the base case analysis,
incremental cost per QALY of VV-MRA was 24,591,939KRW/
QALY (US426,078/QALY) compared with CTA, and EC-MRA
was dominated. The results of sensitivity analysis showed that
the costs of imaging and treatments, and the probabilities of the
treatment options didn’t change the results. The result could be
inﬂuenced by prevalence rate. CONCLUSIONS: VV-MRA tech-
nique was the cost-effective option compared with EC-MRA and
CTA for diagnosis for patients with chronic peripheral arterial
obstructive disease.
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OBJECTIVES: Stroke is the second leading cause of death in
China, and its incidence is expected to increase over the years
despite primary prevention efforts. The aim of this study was to
compare the costs and health effects of stroke rehabilitation
strategies in eastern China. METHODS: A literature review of
the possible stroke rehabilitation strategies was conducted to
compare their impact on costs and health effects. Treatment
effects were based on changes measured using functionality
scales such as the Modiﬁed Barthel Index (MBI). These changes
were transformed into general health-related quality of life
(QOL) improvement according to a generic QOL instrument
(EQ-5D). Costs included direct medical and non-medical costs
but did not include indirect costs. RESULTS: Three different
strategies could be identiﬁed. The ﬁrst strategy is one month of
hospitalization including rehabilitation, which is what most
stroke patients receive. The second is one month of hospitaliza-
tion with rehabilitation for six months. The third strategy is
hospitalization for six months and no active rehabilitation.
Rehabilitation for six months achieves the greatest health
improvement (MBI = 65) but at the greatest cost (RMB34,000),
while one month of hospital including rehabilitation is the least
effective (MBI = 35) and cheapest strategy (RMB19,000 RMB).
Extended hospitalization without rehabilitation results in inter-
mediate costs and effects (MBI = 45 at a cost of RMB29,500).
CONCLUSIONS: Full rehabilitation for six months appears to
be the most cost effective option for stroke patients in China.
Unfortunately, this strategy is out of reach for most Chinese
patients, and this is due to many factors including lack of facili-
ties and skilled personnel. Efforts need to be taken to ﬁnd effec-
tive and cost-effective strategies that can be provided to the
majority of Chinese stroke patients.
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OBJECTIVES: To determine the cost-effectiveness and cost-
utility of Tritace Comb (ramipril+ hydrochlorothiazide) com-
pared to standard therapy of ramipril and hydrochlorothiazide
(HCTZ) used in monotherapy and compared to compound
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therapy of captopril/HCTZ in the treatment of hypertension in
Poland. METHODS: To gain data on clinical effectiveness of
analyzed therapies the clinical effectiveness analysis based on
systematic review of RCTs was conducted. Direct medical costs
regarding drug costs and ambulatory treatment, second-line
therapy, complications and adverse events valid from public
payer perspective were taken into account in the model. Costs
data were gained from National Health Fund in Poland and
medical experts from cardiology and hypertension. Modelling
method applied was a Markov model with a 32 year time
horizon. Sensitivity analyses was performed. The analysis were
done according to HTA guidelines in Poland. RESULTS: Statis-
tically signiﬁcant difference in hypertension reduction between
ramipril/HCTZ and monotherapy with ramipril or HCTZ was
revealed in favour of ramipril/HCTZ. No signiﬁcant differences
in safety proﬁle were found. No signiﬁcant differences in hyper-
tension reduction were observed in comparison to combined
therapy captopril/HCTZ but hypertension control was signiﬁ-
cantly longer for ramipril/HCTZ treatment. The analysis showed
that incremental costs per LYGs were estimated at 1,515 PLN,
6,969 PLN, 10,733 PLN for ramipril/HCTZ compared to rami-
pril, HCTZ or combined therapy captopril/HCTZ, respectively.
Incremental costs per QALY were estimated at 1,925 PLN, 8,800
PLN, 13,930 PLN when comparing ramipril/HCTZ with stan-
dard therapy of ramipril, HCTZ and captopril/HCTZ respec-
tively. Sensitivity analysis showed that the results of the analysis
are robust. CONCLUSIONS: Treatment of hypertension with
Tritace comb (ramipril/HCTZ) compared with a standard mono
therapy (ramipril, HCTZ) and with combined therapy captopril/
HCTZ is very cost-effective option from the public payer’s per-
spective in Poland. Incremental costs per LYG and per QALYs
are below the acceptable threshold for very cost-effectiveness
treatment in Poland (27,000 PLN).
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OBJECTIVES: To evaluate the cost-effectiveness of enoxaparin
compared with unfractionated heparin (UFH) or no prophylaxis
for prevention of venous thromboembolism (VTE) in hospital-
ised medical patients from the Australian hospital perspective.
METHODS: A hypothetical cohort of hospitalised medical
patients was assumed to receive prophylaxis of one of the fol-
lowing: enoxaparin 40 mg once-daily (od); UFH 5000 IU thrice-
daily (tid); UFH 5000 IU bi-daily (bid); no prophylaxis. A
decision-analytic model was constructed using clinical trial data
and local treatment algorithms. Analysis was conducted for all
medical inpatients and a subgroup of patients with ischaemic
stroke. The analysis estimated the incidence of VTE (symptom-
atic DVT and PE), adverse events (heparin-induced throm-
bocytopenia [HIT], prophylaxis and treatment-related major
bleeding), mortality and costs of prophylaxis and treatment
within 30 days and one year of initiating prophylaxis. RESULTS:
In a cohort of 10,000 patients, at 30 days the estimated number
of VTE events was 107 (enoxaparin or UFH tid), 189 (UFH bid)
and 292 (no prophylaxis). Estimated numbers of adverse events
were 54 (enoxaparin), 198 (UFH tid), 199 (UFH bid) and 49 (no
prophylaxis). Estimated total numbers of deaths attributable to
prophylaxis, VTE treatment and adverse events were 27 (enox-
aparin), 40 (UFH tid), 57 (UFH bid) and 63 (no prophylaxis).
Total costs of prophylaxis, diagnostic testing, VTE treatment and
adverse event treatment were AUS$1.1 million (enoxaparin),
AUS$1.7 million (UFH tid), A$1.9 million (UFH bid) and
AUS$1.4 million (no prophylaxis). An additional 12 (enoxaparin
or UFH tid), 21 (UFH bid) or 32 (no prophylaxis) VTE events
were incurred at one year. In patients with ischaemic stroke there
was an enhanced effect of enoxaparin versus other therapies,
with greater cost savings and incremental outcomes. CONCLU-
SIONS: Thromboprophylaxis with enoxaparin prevents VTE
events and related deaths in medical patients, and simulated
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OBJECTIVES: Venous thromboembolism (VTE) is a relevant
cause of morbidity and mortality in patients undergoing major
orthopaedic surgery (MOS). Thromboprophylaxis is recom-
mended in this setting and low-molecular-weight-heparins
(LMWHs) are the anticoagulant agents most frequently used.
Fondaparinux is an effective and safe alternative in this setting.
Objective of our study was to investigate the cost-effectiveness
of fondaparinux versus enoxaparin from the perspective of the
Italian National Health Service (NHS) in patients undergoing
MOS. METHODS: A decision tree model was developed in
order to compare fondaparinux with enoxaprin in extended
thromboprophylaxis of patients undergoing MOS. Probabilities
of symptomatic events were derived from the results of ran-
domized controlled trials; use of resources in common clinical
practice in Italy was evaluated by means of an “ad hoc” ques-
tionnaire administered to a panel of experts. Only direct cost of
VTE (acute treatment of events and of complications) were
included in the analysis. Cost units were derived from current
cost of drugs and from Italian National Healthcare tariffs for
tests and medical visits in 2007 (in Euros). Incremental Cost-
Effectiveness ratios were analysed at three time points: 30 days,
one year, ﬁve years. RESULTS: After 30 days of extended pro-
phylaxis fondaparinux was associated with a lower cost com-
pared with enoxaparin, leading a saving of €48.83 per patient.
At the end of the ﬁrst year after MOS, the saving is increased
to €72.13: rates of late PE and late DVT which are higher with
enoxaparin, particularly for patient undergoing total hip
replacement (which is the 34% of the population of the model),
accounted for this difference. Overall, after 5 years the saving
with fondaparinux is €74.36 per patient. Direct cost of pro-
phylaxis is higher with fondaparinux, but this is highly com-
pensated by the different rates of early DVT, early PE and
prophylaxis-related major bleeding. One-way sensitivity analy-
sis showed that results were robust to the variation in unit costs
for VTE related care or in event rates for both treatments.
CONCLUSIONS: The different rates of early and late DVT, PE
and prophylaxis-related major bleeding overbalanced the lower
cost of enoxaparin, in favour of fondaparinux. Our model sug-
gests that fondaparinux is cost-saving when compared to enox-
aparin for VTE prophylaxis in patients undergoing MOS in
Italy.
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